1. Market Research
  2. > Pseudomonas Infections – Pipeline Review, H1 2013

Pseudomonas Infections – Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 170 pages

Pseudomonas Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Pseudomonas Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pseudomonas Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pseudomonas Infections. Pseudomonas Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pseudomonas Infections.
- A review of the Pseudomonas Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pseudomonas Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pseudomonas Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pseudomonas Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Pseudomonas Infections - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Pseudomonas Infections Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Pseudomonas Infections 10
Pseudomonas Infections Therapeutics under Development by Companies 12
Pseudomonas Infections Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Pseudomonas Infections Therapeutics - Products under Development by Companies 21
Pseudomonas Infections Therapeutics - Products under Investigation by Universities/Institutes 25
Companies Involved in Pseudomonas Infections Therapeutics Development 26
AstraZeneca PLC 26
Targeted Genetics Corporation 27
Merck and Co., Inc. 28
Symphogen A/S 29
Rib-X Pharmaceuticals, Inc. 30
Pfizer Inc. 31
PARI Pharma GmbH 32
Trinity Biosystems, Inc. 33
Insmed Incorporated 34
Intercell AG 35
Basilea Pharmaceutica Ltd. 36
Pevion Biotech Ltd 37
Creative Antibiotics Sweden AB 38
Achaogen Inc. 39
Evolva SA 40
Novabiotics Ltd 41
GlycoVaxyn AG 42
Aridis Pharmaceuticals LLC 43
Mondobiotech Holding AG 44
Polyphor Ltd. 45
Microbiotix, Inc. 46
NanoBio Corporation 47
Sequoia Sciences, Inc. 48
KaloBios Pharmaceuticals, Inc. 49
Ancora Pharmaceuticals Inc. 50
Tetraphase Pharmaceuticals Inc. 51
GlycoMimetics, Inc. 52
Lytix Biopharma AS 53
Phico Therapeutics Ltd. 54
PepTx, Inc. 55
Trana Discovery, Inc. 56
Cantab Biopharmaceuticals Limited 57
Pseudomonas Infections - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Combination Products 59
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
amikacin liposomal - Drug Profile 64
amikacin liposomal - Drug Profile 66
ACHN-975 - Drug Profile 68
Sym-006 - Drug Profile 69
POL-7080 - Drug Profile 70
RX-04 - Drug Profile 71
AR-104 - Drug Profile 72
KBPA-103 - Drug Profile 73
KBPA-102 - Drug Profile 74
KB-001-A - Drug Profile 75
NXL-105 - Drug Profile 77
tobramycin - Drug Profile 78
GMI-1051 - Drug Profile 80
Aerucin - Drug Profile 81
Expanded-Spectrum Aminoglycosides Development Program - Drug Profile 82
ceftobiprole medocaril - Drug Profile 83
gallium citrate Ga 67 - Drug Profile 85
DasKloster-027401 - Drug Profile 86
SLP-0907 - Drug Profile 87
SLP-0901 - Drug Profile 88
SASPject PT3.1 - Drug Profile 89
RX-P763 - Drug Profile 90
RX-P766 - Drug Profile 92
EV-035 - Drug Profile 94
TP-559 - Drug Profile 96
TP-433 - Drug Profile 97
RX-P792 - Drug Profile 99
RX-P793 - Drug Profile 101
RX-P808 - Drug Profile 102
RX-P770 - Drug Profile 103
Gram-Negative Programme - Drug Profile 105
Novarifyn - Drug Profile 106
Gram Negative Antibacterial Programs - Drug Profile 107
PopB-Based Vaccine - Drug Profile 108
PTX-005 - Drug Profile 109
Pseudomonas Program - Drug Profile 110
ACHN-978 - Drug Profile 111
Pseudovac Vaccine - Drug Profile 112
Snare Antibacterial For Gram Negative Infections - Drug Profile 113
(biapenem + RPX-7009) - Drug Profile 114
NB-401 - Drug Profile 115
Vaccine For Pseudomonas - Drug Profile 116
Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 117
BioPhage-PR - Drug Profile 118
Type III Secretion System Inhibitors - Drug Profile 119
Metallo-Beta-Lactamase Inhibitors - Drug Profile 120
Bismith-Thiol Compound For Chronic Wound Infection - Drug Profile 121
Flagellin Fusion Protein Vaccine For Pseudomonas aeruginosa - Drug Profile 122
Antibacterial Program - Drug Profile 124
INP-11252 - Drug Profile 125
CAP37-Derived Antimicrobial Peptides - Drug Profile 126
PEV-10 - Drug Profile 127
Dap-3 Polymyxin Analogs - Drug Profile 128
Pseudomonas Aeruginosa Vaccine - Drug Profile 129
AG-30/5C - Drug Profile 130
Anti-Infectious Glycomimetic Compounds - Drug Profile 131
Vaccine For Pulmonary Pseudomonas Aeruginosa Infections - Drug Profile 132
SASPject PT3.33 - Drug Profile 133
BioPhage-PA - Drug Profile 134
Eskape Bacteria Project - Drug Profile 135
Antimicrobial Compounds Program - Drug Profile 136
Pseudomonas Infections Therapeutics - Drug Profile Updates 137
Pseudomonas Infections Therapeutics - Discontinued Products 156
Pseudomonas Infections Therapeutics - Dormant Products 157
Pseudomonas Infections - Product Development Milestones 158
Featured News and Press Releases 158
Appendix 165
Methodology 165
Coverage 165
Secondary Research 165
Primary Research 165
Expert Panel Validation 165
Contact Us 166
Disclaimer 166

List of Tables

Number of Products Under Development for Pseudomonas Infections, H1 2013 14
Products under Development for Pseudomonas Infections - Comparative Analysis, H1 2013 15
Number of Products under Development by Companies, H1 2013 17
Number of Products under Development by Companies, H1 2013 (Contd..1) 18
Number of Products under Development by Companies, H1 2013 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2013 20
Comparative Analysis by Late Stage Development, H1 2013 21
Comparative Analysis by Mid Clinical Stage Development, H1 2013 22
Comparative Analysis by Early Clinical Stage Development, H1 2013 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 24
Products under Development by Companies, H1 2013 25
Products under Development by Companies, H1 2013 (Contd..1) 26
Products under Development by Companies, H1 2013 (Contd..2) 27
Products under Development by Companies, H1 2013 (Contd..3) 28
Products under Investigation by Universities/Institutes, H1 2013 29
AstraZeneca PLC, H1 2013 30
Targeted Genetics Corporation, H1 2013 31
Merck and Co., Inc., H1 2013 32
Symphogen A/S, H1 2013 33
Rib-X Pharmaceuticals, Inc., H1 2013 34
Pfizer Inc., H1 2013 35
PARI Pharma GmbH, H1 2013 36
Trinity Biosystems, Inc., H1 2013 37
Insmed Incorporated, H1 2013 38
Basilea Pharmaceutica Ltd., H1 2013 40
Pevion Biotech Ltd, H1 2013 41
Creative Antibiotics Sweden AB, H1 2013 42
Achaogen Inc., H1 2013 43
Evolva SA, H1 2013 44
Novabiotics Ltd, H1 2013 45
GlycoVaxyn AG, H1 2013 46
Aridis Pharmaceuticals LLC, H1 2013 47
Mondobiotech Holding AG, H1 2013 48
Polyphor Ltd., H1 2013 49
Microbiotix, Inc., H1 2013 50
NanoBio Corporation, H1 2013 51
Sequoia Sciences, Inc., H1 2013 52
KaloBios Pharmaceuticals, Inc., H1 2013 53
Ancora Pharmaceuticals Inc., H1 2013 54
Tetraphase Pharmaceuticals Inc., H1 2013 55
GlycoMimetics, Inc., H1 2013 56
Lytix Biopharma AS, H1 2013 57
Phico Therapeutics Ltd., H1 2013 58
PepTx, Inc., H1 2013 59
Trana Discovery, Inc., H1 2013 60
Cantab Biopharmaceuticals Limited, H1 2013 61
Assessment by Monotherapy Products, H1 2013 62
Assessment by Combination Products, H1 2013 63
Assessment by Stage and Route of Administration, H1 2013 65
Assessment by Stage and Molecule Type, H1 2013 67
Pseudomonas Infections Therapeutics - Drug Profile Updates 141
Pseudomonas Infections Therapeutics - Discontinued Products 160
Pseudomonas Infections Therapeutics - Dormant Products 161

List of Figures

Number of Products under Development for Pseudomonas Infections, H1 2013 14
Products under Development for Pseudomonas Infections - Comparative Analysis, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 20
Late Stage Products, H1 2013 21
Mid Clinical Stage Products, H1 2013 22
Early Clinical Stage Products, H1 2013 23
Discovery and Pre-Clinical Stage Products, H1 2013 24
Assessment by Monotherapy Products, H1 2013 62
Assessment by Combination Products, H1 2013 63
Assessment by Route of Administration, H1 2013 64
Assessment by Stage and Route of Administration, H1 2013 65
Assessment by Molecule Type, H1 2013 66
Assessment by Stage and Molecule Type, H1 2013 67

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.